Prof. Nils Thoennissen is an international specialist in cancer, chronic degenerative diseases, and regenerative medicine with over 20 years of experience in evidence-based medicine and 14 years of clinical experience in hemotherapy. He has authored 40 scientific publications in peer-reviewed journals and has been awarded 6 awards. He has received postgraduate training at the University of Münster, Cardiff University School of Medicine, University of Mainz, and Cedars-Sinai Medical Center. He currently holds the position of medical director of CBC Health, and has held previous positions as chief physician in St. George Hospital, Kloster Paradies Medical Center, and the University Medical Center Hamburg-Eppendorf.
Read moreDr. Lara is a passionate Honduran-born medical doctor with a Mexican heart. She earned her MD at the Catholic University of Honduras and has an Obesity Medicine post-graduate degree from Universidad Iberoamericana in Mexico City. She continued into a Masters in Applied Nutrition with a focus on research at Universidad Iberoamericana in Mexico City where her commitment to staying up-to-date and her passion for evidence-based medicine grew fonder.
She is member of the International Society for Stem Cell Application, SCOPE certified by the World Obesity Federation, and certified for Sport’s and Exercise Nutrition.
Besides her clinical experience within multiple hospital ER’s and private practice, Dr. Lara has vast experience within the Regenerative Medicine area, where her biggest determination is to positively impact lives of her patients. She has also experience in administrative areas within Mexico, where besides overseeing treatments, she is up-to-date with Mexican regulatory laws (COFEPRIS). Her passions involve medicine and sports where she has managed to combine both, in her professional world as well as within her personal life.
Read moreEducation
Experience
2019-2024
,
(Associate Professor)
Istanbul Private Hisar Intercontinental Hospital
Read moreGATA Haydarpaşa Training and Research Hospital Istanbul, Turkey
Residency program Sep 2011
Infectious Diseases and Clinical Microbiology Department fellowship program.
Gülhane Military Medical Academy Ankara, Turkey
Bachelor of Science: Medical School Aug 2003
Kuleli Military High School Istanbul, Turkey
High School Diploma Jul 1997
Health Sciences University Istanbul, Turkey
Associated Professor of Infectious Diseases Aug 2021 - Current
Associated Professor
Sisli Hamidiye Etfal Training and Research Hospital Istanbul, Turkey
Infectious Diseases Physician July 2020–August 2021
Infectious Diseases Physician
Yale School of Medicine Infectious Diseases Department New Haven, CT, USA
Associate Research Scientist June 2019- June2020
Research to improve vaccine against Tick Borne Diseases (Lyme Diseases, Babesiosis etc.)
Yale School of Medicine Infectious Diseases Department New Haven, CT, USA
Visiting Research Scientist Jul 2018 - June2019
Research to improve vaccine against Tick Borne Diseases (Lyme Diseases, Babesiosis etc.)
Turkish Ministry of Health Ankara, Turkey
Head of Health Tourism unit Feb 2017 - June 2018
Improving the health tourism policy of Turkey.
Sisli Hamidiye Etfal Training and Research Hospital Istanbul, Turkey
Infectious Diseases Physician Aug 2016 - June 2018
Infectious Diseases Physician
Tatvan Military Hospital Bitlis , Turkey
Infectious Diseases Physician Jul 2013 - Aug 2016
Infectious Diseases physician
Girne Military Hospital Turkish Republic of Northern Cyprus
Infectious Diseases Physician Oct 2011 - Jun 2013
Infectious diseases physician
GATA Training and Research Hospital Istanbul, Turkey
Residency period Jul 2006 - Sep 2011
4 th. Mechanized Infantry Brigade Command Edirne, Kesan, Turkey
Medical Doctor, May 2004 - Jun 2006
Maintaining the basic health services of the military unit.
Read more
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Read more
Doctor's visit | price on request |
Umbilical сord blood treatment | $7000 - $9000 |
20 top ranked Umbilical сord blood treatment doctors in the world are represented on this page. The list includes only verified specialists known for their experience and high success rates.
The ranking is composed according to the Bookimed patient reviews and considers the rating of hospitals where doctors practice.
Top 5 Umbilical сord blood treatment doctors on Bookimed.com:
The specialist’s CV contains details about the doctor’s expertise and work experience, education, scientific research, and languages spoken. Compare information on several specialists, read carefully about their experience, success rates, and methods they apply. Make sure the chosen doctor has relevant experience in the treatment of a medical issue you are looking for. Read reviews of patients who had a consultation with the chosen specialist.
Famous Umbilical сord blood treatment doctors have vast experience, continue education constantly, participate in professional associations and have positive feedback from patients treated.
The price for the consultation on Umbilical сord blood treatment varies between experts and depends on certain factors, such as:
To schedule your visit, just submit a request on Bookimed.com. Our coordinator will contact you to discuss the time and details of the appointment, so everything will go smoothly.
We can help to find the right doctors for Umbilical сord blood treatment if you have any difficulties with a choice. Bookimed services are free for patients ♥
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA
ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.
TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.
TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA
ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.
TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.
TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA
ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.
TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.
TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA
ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.
TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.
TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA
ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.
TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.
TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.
MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.
MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES CON FINES TERAPEUTICOS Y DE INVESTIGACION.
MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.
Read moreDoctor's visit | price on request |
Umbilical сord blood treatment | $7000 - $9000 |